Clinical performance was assessed for NIS4®, NIS2+TM, FIB-4, NFS, ELFTM, and ALT for identification of patients with at-risk NASH in patients who were ≥65 years of age. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatohepatitis.